Clinical Trial Search

Primary: Area Under the Concentration-time Curve of Iclepertin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 5329.59; 4812.01; 4090.68…

Primary: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 14h (AUC0-14) — 421.0; 829; 1840.0; 3300.0 nanomole*hours/Liter (nmol∙h/L)

Primary: Area Under the Plasma Concentration-time Curve From 0 to 168 Hours Time Point of BI 425809 (AUC0-168). — 8221.87; 843.57 nanomole*hour/Litre (nmol*h/L)

Primary: Rate of Successful Manufacture of CD22 CAR T Cells — 94; 100; 100 Percentage

Primary: Number of Subjects With Drug-Related Adverse Events (AEs) — 1; 0; 0; 0 Participants

Primary: Severe Hypoglycemia — 0; 0; 0; 0 Participants

Primary: Area Under the Concentration-time Curve of the Analyte ([14C]-BI 425809 After iv Administration as Well as for BI 425809 After Oral Administration) Over the Time…

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs). — 1; 1; 1; 2 Participants

Primary: Mass Balance Recovery of Total [14C]-Radioactivity in Urine (Feurine, 0-t2) — 48.1 Percentage of dose excreted (%)

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 1; 0; 0; 0 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) of Avacopan — 105; 86.7; 108 nanograms per milliliter (ng/mL)

Primary: To Evaluate the Effect of BSS on the Human Gut Microbiome. — 2 Number of different bacterial taxa — p=<0.05

Primary: Treatment-related Adverse Events — 19; 103; 85 Number of Treatment-related Adverse Even

Primary: Number of Participants With Cardiac Toxicity, Defined as Reduction in LVEF of >= 10% Compared to Baseline LVEF and EF =< 50% on the Follow-up Scan, Assessed Using MRI…

Primary: The Proportion of Participants With Adverse Events — 8; 5; 4; 3 Participants